Dr. Sreedhar Katragadda, MD

Dr. Katragadda practices at Cone Health Annie Penn Hospital in Reidsville, North Carolina.

Dr. Katragadda's NPI, 1346484896, was assigned on April 28, 2009. Dr. Katragadda holds North Carolina license 201802469.

Dr. Katragadda's primary practice is Cone Health Annie Penn Hospital, at 618 S Main St, Reidsville, NC 27320 in Rockingham County. The practice phone is (336) 832-7695.

Dr. Katragadda's primary practice is Cone Health Annie Penn Hospital in Reidsville, North Carolina. Dr. Katragadda is also affiliated with BayCare St. Joseph's Hospital. The medical group on file is Cone Health. Dmand AI also links Dr. Katragadda to 4 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Katragadda practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Katragadda's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Katragadda's licenses on file in 2 states: North Carolina and Virginia.

CMS data shows 962 Medicare services from Dr. Katragadda across 6 procedure codes in 2024, for 288 Medicare patients. Medicare paid $62,784 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 288 Medicare patients who saw Dr. Katragadda in 2024. The largest group is 65 to 74, with 118 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Katragadda's median patient age at 72, with 62% women.

In 2024, Dr. Katragadda wrote 4,745 Medicare Part D claims for 516 patients. 84% of them were for generic drugs. CMS names the drug for 4,306 of them, across 86 drugs with 11 or more claims each, at $8,189,535 in total drug cost. In 2023, CMS named 4,029 claims across 84 drugs.

Dr. Katragadda accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Katragadda as offering telehealth.

Dmand AI links 3 papers to Dr. Katragadda in 2021. 2021 was the busiest year, with 2. Dr. Katragadda's most frequent co-authors are Dean F. Bajorin, MD, Jeffrey A. Bogart, MD and Robert Dreicer, MD.

Dmand AI links Dr. Katragadda to 10 clinical trials, 5 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Anal Canal Carcinoma. National Cancer Institute (NCI) sponsors the most, 8.

CMS Open Payments shows 411 general payments to Dr. Katragadda from 57 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Novartis Pharmaceuticals Corporation paid the most, $14,412.